Heat Biologics CEO to Participate in Virtual Panel: "New Approaches to COVID-19: Hidden Breakthroughs," on Thursday, September 10th

Rhea-AI Summary

Heat Biologics (NASDAQ:HTBX) announced that CEO Jeff Wolf will participate in a virtual panel titled, New Approaches to COVID-19: Hidden Breakthroughs, on September 10, 2020, at 1:00 p.m. ET. The discussion features leaders from biopharmaceutical companies exploring solutions to the COVID-19 pandemic. Heat Biologics is focused on developing immune system therapies, including a COVID-19 vaccine and various oncology candidates.

Positive

• CEO Jeff Wolf's participation may enhance visibility for HTBX.
• Heat's active development of multiple oncology candidates and a COVID-19 vaccine could attract investor interest.

Negative

• The COVID-19 vaccine program is still in preclinical development, indicating potential delays in commercialization.

DURHAM, NC / ACCESSWIRE / September 9, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that Jeff Wolf, CEO of Heat Biologics, will participate on a virtual panel, entitled, "New Approaches to COVID-19: Hidden Breakthroughs," being held on Thursday, September 10, 2020 at 1:00 p.m. ET.

The virtual panel discussion will also include: Tom Equels, CEO of AIM ImmunoTech Inc. (AIM); Dr. David Jin, President and CEO of Avalon GlobloCare Corp. (AVCO); Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies Ltd. (IPA) (IPATF) (TQB2) and Vered Caplan, CEO of Orgenesis Inc. (ORGS).

The event brings together executives from leading biopharmaceutical companies to discuss how their companies are helping address the COVID-19 pandemic. The panel will be moderated by broadcast journalist Christine Corrado of Proactive Investors. Investors interested in attending the event can register at: https://zoom.us/webinar/register/8215990551540/WN_YFe8n6dQSm6mpgG3iWfF-w.

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is enrolling in a Phase 1 trial.

For more information, please visit: www.heatbio.com, and also follow us on Twitter.

Media and Investor Relations Contact

David Waldman
+1 919 289 4017
investorrelations@heatbio.com

SOURCE: Heat Biologics, Inc.

View source version on accesswire.com:
https://www.accesswire.com/605211/Heat-Biologics-CEO-to-Participate-in-Virtual-Panel-New-Approaches-to-COVID-19-Hidden-Breakthroughs-on-Thursday-September-10th

FAQ

What is the focus of Heat Biologics, Inc. (HTBX)?

Heat Biologics is focused on developing first-in-class therapies to modulate the immune system, including oncology products and a COVID-19 vaccine.

When is the virtual panel featuring HTBX's CEO taking place?

The virtual panel will occur on September 10, 2020, at 1:00 p.m. ET.

What is the significance of HTBX's CEO participating in the panel?

Jeff Wolf's participation could improve Heat Biologics' visibility and showcase its efforts in addressing COVID-19.

What is the status of Heat Biologics' COVID-19 vaccine development?

The COVID-19 vaccine program is currently in preclinical development.

What other programs is Heat Biologics working on?

Heat Biologics is also developing multiple oncology candidates, including HS-110 in Phase 2 and HS-130 in Phase 1.